A Phase II Study of the Predictive Value of Pharmacokinetic-Adjusted Phenotypic Susceptibility (C12h/IC50) on Antiretroviral Response to Ritonavir-Enhanced Protease Inhibitors in Subjects With Failure of Previous Protease Inhibitor-Based Regimens.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Fosamprenavir; Indinavir; Lopinavir/ritonavir; Ritonavir; Tenofovir disoproxil fumarate
- Indications HIV infections
- Focus Therapeutic Use
- 21 May 2012 Biomarkers information updated
- 03 Apr 2012 Actual patient number is 53 according to ClinicalTrials.gov.
- 03 Apr 2012 Actual end date changed from May 2007 to Jun 2005 as reported by ClinicalTrials.gov.